Liquidia Corporation is a biopharmaceutical company. It develops, manufactures and commercializes products for unmet patient needs principally in the United States. Liquidia Corporation, formerly known as LIQUIDIA TECHNL, is based in Morrisville, North Carolina.
| Revenue (Most Recent Fiscal Year) | $158.32M |
| Net Income (Most Recent Fiscal Year) | $-68.92M |
| PE Ratio (Current Year Earnings Estimate) | 18.56 |
| PE Ratio (Trailing 12 Months) | 393.64 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 17.01 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 45.12 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 9.10% |
| Net Margin (Trailing 12 Months) | 7.74% |
| Return on Equity (Trailing 12 Months) | 46.82% |
| Return on Assets (Trailing 12 Months) | 7.06% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.18 |
| Inventory Turnover (Trailing 12 Months) | 1.13 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.51 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.52 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.80 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.14 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 88.93M |
| Free Float | 66.16M |
| Market Capitalization | $4.90B |
| Average Volume (Last 20 Days) | 1.79M |
| Beta (Past 60 Months) | 0.58 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 25.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 64.54% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |